Moreover, Quintela-Fandino et al. [34] demonstrated a predictive role of [18F]FMISO PET in HER2-negative early breast cancer treated with nintedanib, detecting the patients that did not experience benefit from it based on baseline tumour oxygenation levels and further supporting the potential impact of hypoxia imaging as an early marker of nintedanib efficacy. The gene discussed is ERBB2; the disease is breast carcinoma.